
<?phpxml version="1.0" encoding="utf-8"?>
<rss version="2.0" 
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
>
<channel>
<title>World Pharma News / worldpharmanews / Published News</title>
<link>http://www.worldpharmanews.net</link>
<description>World Pharma News .net - Web 2.0 pharmaceutical news portal</description>
<pubDate>Thu, 08 Jan 2009 00:17:07 +0200</pubDate>
<language>en</language>
<item>
<title><![CDATA[Study sheds new light on aggressive childhood cancer]]></title>
<link>http://www.worldpharmanews.net/Research_Development/Study_sheds_new_light_on_aggressive_childhood_cancer/</link>
<comments>http://www.worldpharmanews.net/Research_Development/Study_sheds_new_light_on_aggressive_childhood_cancer/</comments>
<pubDate>Thu, 08 Jan 2009 00:17:07 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/Study_sheds_new_light_on_aggressive_childhood_cancer/</guid>
<description><![CDATA[EU-funded researchers have uncovered some of the complex molecular mechanisms that drive the growth of neuroblastoma, a type of cancer found in very young children. The scientists hope that their findings, published in the journal Cancer Cell, will lead to the development of new therapies to treat this often aggressive and unpredictable disease.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[U.S. Patent and Trademark Office Accepts Pfizer's Reissue Application on Lipitor]]></title>
<link>http://www.worldpharmanews.net/Product/U-S-_Patent_and_Trademark_Office_Accepts_Pfizers_Reissue_Application_on_Lipitor/</link>
<comments>http://www.worldpharmanews.net/Product/U-S-_Patent_and_Trademark_Office_Accepts_Pfizers_Reissue_Application_on_Lipitor/</comments>
<pubDate>Wed, 07 Jan 2009 00:06:56 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/U-S-_Patent_and_Trademark_Office_Accepts_Pfizers_Reissue_Application_on_Lipitor/</guid>
<description><![CDATA[Pfizer Inc announced today that the U.S. Patent &amp; Trademark Office has issued a &quot;Notice of Allowance&quot; accepting the company's application to correct the technical defect in the '995 enantiomer patent for atorvastatin calcium, the salt form of atorvastatin sold as Lipitor.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[PharmaNews.eu - Dynamic European Pharmaceutical News Engine]]></title>
<link>http://www.worldpharmanews.net/Research_Development/PharmaNews-eu_-_Dynamic_European_Pharmaceutical_News_Engine/</link>
<comments>http://www.worldpharmanews.net/Research_Development/PharmaNews-eu_-_Dynamic_European_Pharmaceutical_News_Engine/</comments>
<pubDate>Wed, 07 Jan 2009 00:06:31 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/PharmaNews-eu_-_Dynamic_European_Pharmaceutical_News_Engine/</guid>
<description><![CDATA[PharmaNews.eu, an advanced web based news project targeting the European pharmaceutical domain, has been launched. The project was developed to directly connect, promote and disseminate the European Industry and Research pharmaceutical achievements with additional focus on the European Commission (EC) and European Medicines Agency (EMEA) news.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Be at Med-e-Tel 2009 to Meet a Highly Qualified eHealth Audience]]></title>
<link>http://www.worldpharmanews.net/Conferences_Events/Be_at_Med-e-Tel_2009_to_Meet_a_Highly_Qualified_eHealth_Audience/</link>
<comments>http://www.worldpharmanews.net/Conferences_Events/Be_at_Med-e-Tel_2009_to_Meet_a_Highly_Qualified_eHealth_Audience/</comments>
<pubDate>Mon, 05 Jan 2009 21:24:04 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Conferences &amp; Events</category>
<guid>http://www.worldpharmanews.net/Conferences_Events/Be_at_Med-e-Tel_2009_to_Meet_a_Highly_Qualified_eHealth_Audience/</guid>
<description><![CDATA[1-3 April, 2009, LuxembourgAn extensive international program with participants from 50 countries in Europe and around the world will put your company and solutions in front of an audience that is looking to see and hear the latest developments in telemedicine and eHealth. Supported by the International Society for Telemedicine &amp; eHealth, European Commission, World Health Organization, International Telecommunication Union, European Association of CyberTherapy &amp; Rehabilitation, and a range of other associations, the Med-e-Tel event gathers European and global healthcare leaders and providers.<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[FDA Approves Drug for Patients with Advanced Prostate Cancer]]></title>
<link>http://www.worldpharmanews.net/Product/FDA_Approves_Drug_for_Patients_with_Advanced_Prostate_Cancer/</link>
<comments>http://www.worldpharmanews.net/Product/FDA_Approves_Drug_for_Patients_with_Advanced_Prostate_Cancer/</comments>
<pubDate>Wed, 31 Dec 2008 12:20:50 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/FDA_Approves_Drug_for_Patients_with_Advanced_Prostate_Cancer/</guid>
<description><![CDATA[The U.S. Food and Drug Administration recently approved the injectable drug degarelix, the first new drug in several years for prostate cancer. Degarelix is intended to treat patients with advanced prostate cancer. It belongs to a class of agents called gonadotropin releasing hormone (GnRH) receptor inhibitors. These agents slow the growth and progression of prostate cancer by suppressing testosterone, which plays an important role in the continued growth of prostate cancer.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Novo Nordisk and VLST Corporation announce collaboration agreement]]></title>
<link>http://www.worldpharmanews.net/Financial/Novo_Nordisk_and_VLST_Corporation_announce_collaboration_agreement/</link>
<comments>http://www.worldpharmanews.net/Financial/Novo_Nordisk_and_VLST_Corporation_announce_collaboration_agreement/</comments>
<pubDate>Tue, 30 Dec 2008 00:48:15 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Novo_Nordisk_and_VLST_Corporation_announce_collaboration_agreement/</guid>
<description><![CDATA[Novo Nordisk and VLST Corporation, a Seattle-based biotechnology company focused on the development of therapeutics for autoimmune and inflammatory disorders, have entered into an exclusive, worldwide collaboration agreement to develop therapeutic targets utilising VLST's technology platform in the fields of autoimmune and inflammatory disorders.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[GlaxoSmithKline to cease providing corporate political contributions]]></title>
<link>http://www.worldpharmanews.net/Corporate/GlaxoSmithKline_to_cease_providing_corporate_political_contributions/</link>
<comments>http://www.worldpharmanews.net/Corporate/GlaxoSmithKline_to_cease_providing_corporate_political_contributions/</comments>
<pubDate>Wed, 24 Dec 2008 22:51:22 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Corporate</category>
<guid>http://www.worldpharmanews.net/Corporate/GlaxoSmithKline_to_cease_providing_corporate_political_contributions/</guid>
<description><![CDATA[GlaxoSmithKline has announced a new global policy to voluntarily stop all corporate political contributions. In the past, GSK - in common with many companies and in full compliance with local laws - has made a number of corporate contributions in countries such as the US and Canada. GSK's new policy will ensure that no such contributions will be made in the future.<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Glivec shows significant benefit for gastrointestinal stromal tumor (GIST) patients]]></title>
<link>http://www.worldpharmanews.net/Product/Glivec_shows_significant_benefit_for_gastrointestinal_stromal_tumor_GIST_patients/</link>
<comments>http://www.worldpharmanews.net/Product/Glivec_shows_significant_benefit_for_gastrointestinal_stromal_tumor_GIST_patients/</comments>
<pubDate>Tue, 23 Dec 2008 00:04:23 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Glivec_shows_significant_benefit_for_gastrointestinal_stromal_tumor_GIST_patients/</guid>
<description><![CDATA[Glivec (imatinib) has been approved by the US Food and Drug Administration (FDA) for the post-surgery treatment of adult patients following complete surgical removal of Kit (CD117)-positive gastrointestinal stromal tumors (GIST).<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[AstraZeneca and MAP Pharmaceuticals Announce Worldwide Collaboration]]></title>
<link>http://www.worldpharmanews.net/Financial/AstraZeneca_and_MAP_Pharmaceuticals_Announce_Worldwide_Collaboration/</link>
<comments>http://www.worldpharmanews.net/Financial/AstraZeneca_and_MAP_Pharmaceuticals_Announce_Worldwide_Collaboration/</comments>
<pubDate>Mon, 22 Dec 2008 01:32:17 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/AstraZeneca_and_MAP_Pharmaceuticals_Announce_Worldwide_Collaboration/</guid>
<description><![CDATA[AstraZeneca and MAP Pharmaceuticals, Inc. have announced an exclusive worldwide agreement to develop and commercialise Unit Dose Budesonide (UDB), MAP Pharmaceuticals' proprietary nebulised formulation of budesonide. UDB is being developed by MAP Pharmaceuticals as a potential treatment for paediatric asthma and is currently in Phase III clinical development. UDB has the potential to be nebulised more quickly and at a lower nominal dose than the commercially available product.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Healthcare Costs Prevented Almost 40 Million Americans from Filling Their Prescriptions in 2008]]></title>
<link>http://www.worldpharmanews.net/Research_Development/Healthcare_Costs_Prevented_Almost_40_Million_Americans_from_Filling_Their_Prescriptions_in_2008/</link>
<comments>http://www.worldpharmanews.net/Research_Development/Healthcare_Costs_Prevented_Almost_40_Million_Americans_from_Filling_Their_Prescriptions_in_2008/</comments>
<pubDate>Sat, 20 Dec 2008 00:07:29 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/Healthcare_Costs_Prevented_Almost_40_Million_Americans_from_Filling_Their_Prescriptions_in_2008/</guid>
<description><![CDATA[Nearly 40 million U.S. adults decided not to fill a prescription medication from a doctor in the past year because of the cost, according to pharmaceutical and healthcare market research company Manhattan Research's Cybercitizen Healtha4 v8.0 consumer study and strategic advisory service. The study found that women and patients with neurological and mental health conditions were the most likely to give up their medication due to cost.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[New semantics in GoPubMed and European biotech start-ups]]></title>
<link>http://www.worldpharmanews.net/Research_Development/New_semantics_in_GoPubMed_and_European_biotech_start-ups/</link>
<comments>http://www.worldpharmanews.net/Research_Development/New_semantics_in_GoPubMed_and_European_biotech_start-ups/</comments>
<pubDate>Fri, 19 Dec 2008 00:06:24 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/New_semantics_in_GoPubMed_and_European_biotech_start-ups/</guid>
<description><![CDATA[Transinsight has announced the launch of GoPubMed.com version 4.0, the semantic search engine for the life sciences with significantly improved features.- Increased Speed: GoPubMed 4.0 is ten times faster than its predecessor, now handling millions of documents in seconds.- Intelligent search: Never miss a document. The new interactive filtering process reduces millions of documents to a handful of key papers in just a few clicks. The Web 2.0 query processing helps by suggesting search ideas as you type.- More document sources: The GoPubMed.com website offers searches on PubMed and the Web at no cost. The professional version of GoPubMed PRO is designed to include intranet searches and patents.- Improve GoPubMed: The public website GoPubMed.com allows users to manually annotate and verify papers including their background information. The platform has already about 60.000 enthusiastic helping hands. GoPubMed shows the semantic path to the future: community generated ontologies and so improves the quality of search results.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Metabolic disturbances indicate progress of the disease even years in advance]]></title>
<link>http://www.worldpharmanews.net/Research_Development/Metabolic_disturbances_indicate_progress_of_the_disease_even_years_in_advance/</link>
<comments>http://www.worldpharmanews.net/Research_Development/Metabolic_disturbances_indicate_progress_of_the_disease_even_years_in_advance/</comments>
<pubDate>Thu, 18 Dec 2008 00:05:54 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/Metabolic_disturbances_indicate_progress_of_the_disease_even_years_in_advance/</guid>
<description><![CDATA[Finnish scientists have reported a breakthrough in the attempts to understand the development of type 1 diabetes. They discovered disturbances in lipid and amino acid metabolism in children who later progressed to type 1 diabetes, also known as juvenile diabetes. The alterations preceded the autoimmune response by months to years. The study may prompt new approaches for prediction and prevention of type 1 diabetes in pre-autoimmune phase of the disease.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management]]></title>
<link>http://www.worldpharmanews.net/Product/First_and_Only_Fibrate_Indicated_for_Use_in_Combination_With_a_Statin_for_Cholesterol_Management/</link>
<comments>http://www.worldpharmanews.net/Product/First_and_Only_Fibrate_Indicated_for_Use_in_Combination_With_a_Statin_for_Cholesterol_Management/</comments>
<pubDate>Wed, 17 Dec 2008 00:14:09 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/First_and_Only_Fibrate_Indicated_for_Use_in_Combination_With_a_Statin_for_Cholesterol_Management/</guid>
<description><![CDATA[The U.S. Food and Drug Administration (FDA) has approved Abbott's TRILIPIX(TM) (fenofibric acid) delayed-release capsules for use along with diet to help lower triglycerides and LDL cholesterol, and to raise HDL cholesterol in patients with lipid problems. TRILIPIX is the first and only fibrate to be approved for use in combination with a statin. In certain patients, treatment guidelines recommend the combination of a fibrate with a statin to further improve lipid levels. TRILIPIX has not been shown to prevent heart disease or heart attack.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[FDA's Monthly Video Series Wins Award]]></title>
<link>http://www.worldpharmanews.net/Research_Development/FDAs_Monthly_Video_Series_Wins_Award/</link>
<comments>http://www.worldpharmanews.net/Research_Development/FDAs_Monthly_Video_Series_Wins_Award/</comments>
<pubDate>Wed, 17 Dec 2008 00:13:57 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/FDAs_Monthly_Video_Series_Wins_Award/</guid>
<description><![CDATA[&quot;FDA Patient Safety News,&quot; the FDA's monthly video series for health care professionals, has won the Cheers Award from the Institute for Safe Medication Practices (ISMP) for efforts to improve the safe use of medical products and prevent medical errors.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Bayer innovations provide solutions for the global challenges of the future]]></title>
<link>http://www.worldpharmanews.net/Research_Development/Bayer_innovations_provide_solutions_for_the_global_challenges_of_the_future/</link>
<comments>http://www.worldpharmanews.net/Research_Development/Bayer_innovations_provide_solutions_for_the_global_challenges_of_the_future/</comments>
<pubDate>Tue, 16 Dec 2008 00:04:35 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/Bayer_innovations_provide_solutions_for_the_global_challenges_of_the_future/</guid>
<description><![CDATA[The Bayer Group is to further expand its research and development activities despite the current financial and economic crisis. &quot;The task now is to set the right course. Only through innovation can our company generate the growth that is essential to safeguard its sustained success,&quot; said Werner Wenning, Chairman of the Board of Management of Bayer AG, in an address given in front of 130 journalists during the &quot;Bayer's Perspective on Innovation 2008&quot; press forum in Leverkusen. In 2008 the company's research and development budget is at around EUR 2.8 billion. &quot;This represents the biggest R&amp;D budget in Germany in the chemical and pharmaceutical sector - and amounts to about five percent of all research and development spending by German industry as a whole,&quot; explained Wenning. Bayer will continue in the future to commit itself to strong research and development.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Expert System for Automatic Analysis of Data Quality in Clinical Trials]]></title>
<link>http://www.worldpharmanews.net/Research_Development/Expert_System_for_Automatic_Analysis_of_Data_Quality_in_Clinical_Trials/</link>
<comments>http://www.worldpharmanews.net/Research_Development/Expert_System_for_Automatic_Analysis_of_Data_Quality_in_Clinical_Trials/</comments>
<pubDate>Sat, 13 Dec 2008 00:56:15 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/Expert_System_for_Automatic_Analysis_of_Data_Quality_in_Clinical_Trials/</guid>
<description><![CDATA[In the framework of the development scheme 'Central Innovation Scheme for Medium-sized Businesses' of the German Federal Ministry for Economics and Technology (BMWI), clinIT AG, based in Freiburg, Germany, has been awarded a six-figure federal grant in cooperation with the Institute for Informatics of the Albert-Ludwigs-University Freiburg, Faculty for Data Bases and Information Systems.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Strengthening pharmacovigilance to reduce adverse effects of medicines]]></title>
<link>http://www.worldpharmanews.net/Research_Development/Strengthening_pharmacovigilance_to_reduce_adverse_effects_of_medicines/</link>
<comments>http://www.worldpharmanews.net/Research_Development/Strengthening_pharmacovigilance_to_reduce_adverse_effects_of_medicines/</comments>
<pubDate>Fri, 12 Dec 2008 00:06:40 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/Strengthening_pharmacovigilance_to_reduce_adverse_effects_of_medicines/</guid>
<description><![CDATA[Medicinal products contribute considerably to the health of EU citizens. They can, however, also have adverse effects. It is estimated that 5% of all hospital admissions are due to an adverse drug reaction (ADR), and that ADR is the fifth most common cause of hospital death. In light of experience and following an assessment made of the EU pharmacovigilance system (supervision and monitoring of ADR) made by the Commission it has become clear that new measures are necessary to improve how the EU rules operate on the pharmacovigilance of medicinal products. Today's proposals seek to change the existing EU legislation on pharmacovigilance (provisions in Regulation (EC) No 726/2004 and Directive 2001/83/EC). They aim at strengthening and rationalizing the EU pharmacovigilance system, with the overall objectives of better protecting public health, ensuring proper functioning of the internal market and simplifying the current procedures.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Roche and Axiogenesis Enter into Co-Development and Marketing Agreement]]></title>
<link>http://www.worldpharmanews.net/Product/Roche_and_Axiogenesis_Enter_into_Co-Development_and_Marketing_Agreement/</link>
<comments>http://www.worldpharmanews.net/Product/Roche_and_Axiogenesis_Enter_into_Co-Development_and_Marketing_Agreement/</comments>
<pubDate>Thu, 11 Dec 2008 00:05:41 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Roche_and_Axiogenesis_Enter_into_Co-Development_and_Marketing_Agreement/</guid>
<description><![CDATA[Roche and Axiogenesis AG, Cologne, Germany have entered into an agreement for the development and distribution for Axiogenesis' Cor.At(R) 100% pure cardiomyocytes platform as an integral part of the xCELLigence life cell analysis system. Under the terms of the agreement, RAS will market cell-systems, based on the technology of Axiogenesis Cor.At being customize for the xCELLigence platform.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pfizer and Sigma-Tau Announce an Agreement to Market a Potential New Treatment for Malaria]]></title>
<link>http://www.worldpharmanews.net/Product/Pfizer_and_Sigma-Tau_Announce_an_Agreement_to_Market_a_Potential_New_Treatment_for_Malaria/</link>
<comments>http://www.worldpharmanews.net/Product/Pfizer_and_Sigma-Tau_Announce_an_Agreement_to_Market_a_Potential_New_Treatment_for_Malaria/</comments>
<pubDate>Thu, 11 Dec 2008 00:05:26 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Pfizer_and_Sigma-Tau_Announce_an_Agreement_to_Market_a_Potential_New_Treatment_for_Malaria/</guid>
<description><![CDATA[Pfizer Inc (Pfizer) and Sigma-Tau Industrie Farmaceutiche Riunite S.p.A (Sigma-Tau), a privately owned Italian pharmaceutical company, have entered into a license and supply agreement under which, following applicable regulatory submissions and approvals, the companies will market Eurartesim, a novel fixed dose artemisinin-based combination therapy (ACT), in Africa.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[AstraZeneca and Bristol-Myers Squibb Announce Expansion of Worldwide Collaboration]]></title>
<link>http://www.worldpharmanews.net/Corporate/AstraZeneca_and_Bristol-Myers_Squibb_Announce_Expansion_of_Worldwide_Collaboration/</link>
<comments>http://www.worldpharmanews.net/Corporate/AstraZeneca_and_Bristol-Myers_Squibb_Announce_Expansion_of_Worldwide_Collaboration/</comments>
<pubDate>Wed, 10 Dec 2008 00:05:55 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Corporate</category>
<guid>http://www.worldpharmanews.net/Corporate/AstraZeneca_and_Bristol-Myers_Squibb_Announce_Expansion_of_Worldwide_Collaboration/</guid>
<description><![CDATA[AstraZeneca and Bristol-Myers Squibb have announced expansion of their worldwide collaboration to include the development and commercialisation of dapagliflozin in Japan. Dapagliflozin, one of two investigational drugs under joint development by the companies, is currently being studied in Phase III clinical trials in several countries, including the U.S., to assess its efficacy and safety as a once-daily treatment for type 2 diabetes.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[GSK analysis shows Seretide/Advair is a well tolerated and effective medicine]]></title>
<link>http://www.worldpharmanews.net/Product/GSK_analysis_shows_SeretideAdvair_is_a_well_tolerated_and_effective_medicine/</link>
<comments>http://www.worldpharmanews.net/Product/GSK_analysis_shows_SeretideAdvair_is_a_well_tolerated_and_effective_medicine/</comments>
<pubDate>Tue, 09 Dec 2008 07:01:26 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/GSK_analysis_shows_SeretideAdvair_is_a_well_tolerated_and_effective_medicine/</guid>
<description><![CDATA[The U.S. Food and Drug Administration has posted a comprehensive review conducted by GlaxoSmithKline of its clinical and observational data that demonstrated better overall asthma control with the combination medicine Seretide/Advair (fluticasone propionate and salmeterol) than with a single medicine alone. The data also presents the well-established safety record for Seretide/Advair.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Innovators from Global Biopharma Companies Discuss Consumer & Physician E-marketing Trends]]></title>
<link>http://www.worldpharmanews.net/Research_Development/Innovators_from_Global_Biopharma_Companies_Discuss_Consumer__Physician_E-marketing_Trends/</link>
<comments>http://www.worldpharmanews.net/Research_Development/Innovators_from_Global_Biopharma_Companies_Discuss_Consumer__Physician_E-marketing_Trends/</comments>
<pubDate>Sat, 06 Dec 2008 15:29:26 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/Innovators_from_Global_Biopharma_Companies_Discuss_Consumer__Physician_E-marketing_Trends/</guid>
<description><![CDATA[In recent years European healthcare consumers and physicians have steadily increased their use of the Internet for treatment and product decisions. According to healthcare and pharmaceutical market research company's Manhattan Research's Cybercitizen Healtha4 Europe v8.0 study and strategy advisory service, over 150 million adults in countries across Europe used online channels to access health information in 2008.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Bayer Schering Pharma expands men's healthcare portfolio]]></title>
<link>http://www.worldpharmanews.net/Product/Bayer_Schering_Pharma_expands_mens_healthcare_portfolio/</link>
<comments>http://www.worldpharmanews.net/Product/Bayer_Schering_Pharma_expands_mens_healthcare_portfolio/</comments>
<pubDate>Fri, 05 Dec 2008 19:03:37 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Bayer_Schering_Pharma_expands_mens_healthcare_portfolio/</guid>
<description><![CDATA[Bayer Schering Pharma will develop and commercialise ProStrakan's Tostrex in Canada, Latin America, the Middle East, Africa, Asia and the Pacific region. A respective agreement between Bayer Schering Pharma and ProStrakan Group plc. was signed which grants Bayer exclusive marketing rights in these regions.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Children in the world's poorest countries to get free insulin]]></title>
<link>http://www.worldpharmanews.net/Corporate/Children_in_the_worlds_poorest_countries_to_get_free_insulin/</link>
<comments>http://www.worldpharmanews.net/Corporate/Children_in_the_worlds_poorest_countries_to_get_free_insulin/</comments>
<pubDate>Fri, 05 Dec 2008 00:24:16 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Corporate</category>
<guid>http://www.worldpharmanews.net/Corporate/Children_in_the_worlds_poorest_countries_to_get_free_insulin/</guid>
<description><![CDATA[Novo Nordisk has announced that it will provide diabetes care, including free insulin, to 10,000 children in some of the world's poorest countries. The five-year programme, called 'Changing the Future for Children with Diabetes', will begin in 2009 with an initial roll-out in Uganda, Tanzania, Guinea-Conakry and the Democratic Republic of Congo.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[New discovery: lethal fungus reproduces sexually]]></title>
<link>http://www.worldpharmanews.net/Research_Development/New_discovery_lethal_fungus_reproduces_sexually/</link>
<comments>http://www.worldpharmanews.net/Research_Development/New_discovery_lethal_fungus_reproduces_sexually/</comments>
<pubDate>Thu, 04 Dec 2008 00:05:59 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/New_discovery_lethal_fungus_reproduces_sexually/</guid>
<description><![CDATA[Researchers in Ireland and the UK have found that a lethal fungus, Aspergillus fumigatus, reproduces sexually. The findings represent a major breakthrough in the understanding of this pathogen, which causes death in 50% of infected immune-deficient patients. The study was funded in part by a Marie Curie grant from the EU and is published in the journal Nature.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[New mouse model for study of Creutzfeldt-Jakob disease]]></title>
<link>http://www.worldpharmanews.net/Research_Development/New_mouse_model_for_study_of_Creutzfeldt-Jakob_disease/</link>
<comments>http://www.worldpharmanews.net/Research_Development/New_mouse_model_for_study_of_Creutzfeldt-Jakob_disease/</comments>
<pubDate>Tue, 02 Dec 2008 00:09:22 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/New_mouse_model_for_study_of_Creutzfeldt-Jakob_disease/</guid>
<description><![CDATA[Italian researchers have bred mice that exhibit similar deficits to those experienced by people with Creutzfeldt-Jakob disease, a prion disease similar to bovine spongiform encephalopathy. The EU-funded study, published in the journal Neuron, provides insights that may help to diagnose prion diseases early, when therapeutic intervention may be effective.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Roche signs definitive agreement to acquire Memory Pharmaceuticals]]></title>
<link>http://www.worldpharmanews.net/Financial/Roche_signs_definitive_agreement_to_acquire_Memory_Pharmaceuticals/</link>
<comments>http://www.worldpharmanews.net/Financial/Roche_signs_definitive_agreement_to_acquire_Memory_Pharmaceuticals/</comments>
<pubDate>Tue, 02 Dec 2008 00:09:12 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Roche_signs_definitive_agreement_to_acquire_Memory_Pharmaceuticals/</guid>
<description><![CDATA[Roche and Memory Pharmaceuticals have announced that the two companies have signed a definitive merger agreement for Roche to fully acquire Memory in an all-cash transaction at a price of approximately USD 50 million.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[4th Annual eMarketing Summit Europe 2009]]></title>
<link>http://www.worldpharmanews.net/Conferences_Events/4th_Annual_eMarketing_Summit_Europe_2009/</link>
<comments>http://www.worldpharmanews.net/Conferences_Events/4th_Annual_eMarketing_Summit_Europe_2009/</comments>
<pubDate>Sat, 29 Nov 2008 11:12:58 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Conferences &amp; Events</category>
<guid>http://www.worldpharmanews.net/Conferences_Events/4th_Annual_eMarketing_Summit_Europe_2009/</guid>
<description><![CDATA[April 27-28, 2009, Munich, Germany.eyeforpharma's leading eMarketing Summit returns for it's forth successful year with a new format and new concepts for 2009, you'll hear from the most experienced and innovative eMarketing experts and enjoy an interactive hands-on learning experience.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pfizer's Novel HIV/AIDS Treatment SELZENTRY]]></title>
<link>http://www.worldpharmanews.net/Product/Pfizers_Novel_HIVAIDS_Treatment_SELZENTRY/</link>
<comments>http://www.worldpharmanews.net/Product/Pfizers_Novel_HIVAIDS_Treatment_SELZENTRY/</comments>
<pubDate>Fri, 28 Nov 2008 00:05:23 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Pfizers_Novel_HIVAIDS_Treatment_SELZENTRY/</guid>
<description><![CDATA[The U.S. Food and Drug Administration (FDA) has granted SELZENTRYa4 (maraviroc) full (traditional) approval for use in treatment-experienced adults with CCR5-tropic HIV-1 in combination with other antiretrovirals. SELZENTRY was originally granted accelerated conditional approval in August 2007 based on 24-week data from pivotal Phase 3 studies. SELZENTRY now becomes the latest fully approved treatment for HIV.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[AstraZeneca Settles US Pulmicort Respules Patent Litigation with Teva]]></title>
<link>http://www.worldpharmanews.net/Corporate/AstraZeneca_Settles_US_Pulmicort_Respules_Patent_Litigation_with_Teva/</link>
<comments>http://www.worldpharmanews.net/Corporate/AstraZeneca_Settles_US_Pulmicort_Respules_Patent_Litigation_with_Teva/</comments>
<pubDate>Thu, 27 Nov 2008 00:04:42 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Corporate</category>
<guid>http://www.worldpharmanews.net/Corporate/AstraZeneca_Settles_US_Pulmicort_Respules_Patent_Litigation_with_Teva/</guid>
<description><![CDATA[AstraZeneca has entered into a settlement agreement in its Pulmicort Respules patent infringement litigation against Ivax Pharmaceuticals, Inc., a wholly owned subsidiary of Teva Pharmaceuticals USA. The agreement settles the patent infringement litigation filed by AstraZeneca following Teva's submission to the United States Food &amp; Drug Administration of an Abbreviated New Drug Application for a generic version of Pulmicort Respules. Under the settlement agreement, Teva concedes that the patents asserted by AstraZeneca in the patent litigation are valid and enforceable. Teva also concedes that its generic version of Pulmicort Respules infringes AstraZeneca's patents.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Sandoz receives positive EU opinion for biosimilar filgrastim]]></title>
<link>http://www.worldpharmanews.net/Product/Sandoz_receives_positive_EU_opinion_for_biosimilar_filgrastim/</link>
<comments>http://www.worldpharmanews.net/Product/Sandoz_receives_positive_EU_opinion_for_biosimilar_filgrastim/</comments>
<pubDate>Thu, 27 Nov 2008 00:04:31 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Sandoz_receives_positive_EU_opinion_for_biosimilar_filgrastim/</guid>
<description><![CDATA[Sandoz has received a positive opinion from European regulators for its third biosimilar medicine, filgrastim, marking another important milestone in its efforts to bring affordable high-quality biopharmaceuticals to patients worldwide.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Johnson & Johnson Announces Definitive Agreement to Acquire Omrix]]></title>
<link>http://www.worldpharmanews.net/Financial/Johnson__Johnson_Announces_Definitive_Agreement_to_Acquire_Omrix/</link>
<comments>http://www.worldpharmanews.net/Financial/Johnson__Johnson_Announces_Definitive_Agreement_to_Acquire_Omrix/</comments>
<pubDate>Wed, 26 Nov 2008 00:12:09 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Johnson__Johnson_Announces_Definitive_Agreement_to_Acquire_Omrix/</guid>
<description><![CDATA[Johnson &amp; Johnson (NYSE: JNJ) and Omrix Biopharmaceuticals, Inc. (NASDAQ: OMRI), a fully integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, have announced a definitive agreement whereby Omrix will be acquired for approximately $438 million in a cash tender offer. Omrix is expected to operate as a stand-alone entity reporting through ETHICON, Inc., a Johnson &amp; Johnson company and leading provider of suture, mesh, hemostats and other products for a wide range of surgical procedures.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[GSK and Neptunus form joint venture for the co-development of flu vaccines]]></title>
<link>http://www.worldpharmanews.net/Corporate/GSK_and_Neptunus_form_joint_venture_for_the_co-development_of_flu_vaccines/</link>
<comments>http://www.worldpharmanews.net/Corporate/GSK_and_Neptunus_form_joint_venture_for_the_co-development_of_flu_vaccines/</comments>
<pubDate>Tue, 25 Nov 2008 00:06:57 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Corporate</category>
<guid>http://www.worldpharmanews.net/Corporate/GSK_and_Neptunus_form_joint_venture_for_the_co-development_of_flu_vaccines/</guid>
<description><![CDATA[GlaxoSmithKline (GSK) has signed an exclusive Cooperation Agreement with Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. (NIBT) as a preliminary step in forming a Joint Venture (JV) between the two companies. The agreement outlines the proposed terms for establishing a JV company, which will seek to co-develop seasonal influenza vaccines and pre-pandemic/pandemic influenza vaccines, firstly targeting against strains of the virus specific to China, Hong Kong and Macau.<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[AstraZeneca to divest Nordic over-the-counter portfolio]]></title>
<link>http://www.worldpharmanews.net/Financial/AstraZeneca_to_divest_Nordic_over-the-counter_portfolio/</link>
<comments>http://www.worldpharmanews.net/Financial/AstraZeneca_to_divest_Nordic_over-the-counter_portfolio/</comments>
<pubDate>Mon, 24 Nov 2008 00:05:28 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/AstraZeneca_to_divest_Nordic_over-the-counter_portfolio/</guid>
<description><![CDATA[AstraZeneca has announced the divestment to GlaxoSmithKline of a portfolio of over-the-counter (OTC) products predominantly sold in Sweden. The decision reinforces AstraZeneca's strategy to focus on innovation in prescription medicines.<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[EMEA recommends the suspension of the marketing authorisation of Ionsys (fentanyl hydrochloride)]]></title>
<link>http://www.worldpharmanews.net/Product/EMEA_recommends_the_suspension_of_the_marketing_authorisation_of_Ionsys_fentanyl_hydrochloride/</link>
<comments>http://www.worldpharmanews.net/Product/EMEA_recommends_the_suspension_of_the_marketing_authorisation_of_Ionsys_fentanyl_hydrochloride/</comments>
<pubDate>Sat, 22 Nov 2008 11:08:16 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/EMEA_recommends_the_suspension_of_the_marketing_authorisation_of_Ionsys_fentanyl_hydrochloride/</guid>
<description><![CDATA[The European Medicines Agency (EMEA) has recommended the suspension of the marketing authorisation of Ionsys (fentanyl hydrochloride), from Janssen-Cilag International NV, because of a defect with the delivery system of the medicine that could lead to patients being overdosed.<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pfizer withdraws its application to change the marketing authorisation for Viagra]]></title>
<link>http://www.worldpharmanews.net/Product/Pfizer_withdraws_its_application_to_change_the_marketing_authorisation_for_Viagra/</link>
<comments>http://www.worldpharmanews.net/Product/Pfizer_withdraws_its_application_to_change_the_marketing_authorisation_for_Viagra/</comments>
<pubDate>Sat, 22 Nov 2008 11:08:04 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Pfizer_withdraws_its_application_to_change_the_marketing_authorisation_for_Viagra/</guid>
<description><![CDATA[The European Medicines Agency (EMEA) has been formally notified by Pfizer Limited of its decision to withdraw its application for a change to the marketing authorisation for the medicine Viagra (sildenafil) 50 mg film-coated tablets. The change concerned switching the classification of the medicine from 'medicinal product subject to medical prescription' to 'medicinal product not subject to medical prescription' (an over-the-counter [OTC] medicine).<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[AstraZeneca granted Temporary Restraining Order in PULMICORT RESPULES patent litigation]]></title>
<link>http://www.worldpharmanews.net/Corporate/AstraZeneca_granted_Temporary_Restraining_Order_in_PULMICORT_RESPULES_patent_litigation/</link>
<comments>http://www.worldpharmanews.net/Corporate/AstraZeneca_granted_Temporary_Restraining_Order_in_PULMICORT_RESPULES_patent_litigation/</comments>
<pubDate>Fri, 21 Nov 2008 00:07:26 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Corporate</category>
<guid>http://www.worldpharmanews.net/Corporate/AstraZeneca_granted_Temporary_Restraining_Order_in_PULMICORT_RESPULES_patent_litigation/</guid>
<description><![CDATA[On 19 November 2008, AstraZeneca was granted a Temporary Restraining Order (TRO) by the United States District Court for the District of New Jersey, halting sales of Teva's budesonide inhalation suspension product, a generic version of AstraZeneca's PULMICORT RESPULES treatment.<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[UK's Government and Industry in drug price deal]]></title>
<link>http://www.worldpharmanews.net/Research_Development/UKs_Government_and_Industry_in_drug_price_deal/</link>
<comments>http://www.worldpharmanews.net/Research_Development/UKs_Government_and_Industry_in_drug_price_deal/</comments>
<pubDate>Fri, 21 Nov 2008 00:06:39 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/UKs_Government_and_Industry_in_drug_price_deal/</guid>
<description><![CDATA[A new deal has been reached between the UK's Government and the pharmaceutical industry means that more patients will benefit from a wider range of innovative drug treatments at a fair price to the NHS. The flexible pricing scheme agreed will ensure that medicines fairly reflect their value to patients, branded drugs will see their price cut, and industry innovations will be encouraged and rewarded. As a result, patients will have faster access to new medicines that are clinically and cost effective.<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of All Infants]]></title>
<link>http://www.worldpharmanews.net/Product/Russia_Chooses_Inactivated_Polio_Vaccine_from_Sanofi_Pasteur_for_Primary_Immunization_of_All_Infants/</link>
<comments>http://www.worldpharmanews.net/Product/Russia_Chooses_Inactivated_Polio_Vaccine_from_Sanofi_Pasteur_for_Primary_Immunization_of_All_Infants/</comments>
<pubDate>Thu, 20 Nov 2008 00:04:47 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Russia_Chooses_Inactivated_Polio_Vaccine_from_Sanofi_Pasteur_for_Primary_Immunization_of_All_Infants/</guid>
<description><![CDATA[Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced that Russia has chosen inactivated polio vaccine (IPV) from Sanofi Pasteur for primary immunization of all infants. The IPV doses are provided by M.P. Chumakov Institute of Poliomyelitis and Virus Encephalitides through a manufacturing agreement with Sanofi Pasteur.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Manhattan Research Releases Report on the Future of Physician Customer Service Portals]]></title>
<link>http://www.worldpharmanews.net/Research_Development/Manhattan_Research_Releases_Report_on_the_Future_of_Physician_Customer_Service_Portals/</link>
<comments>http://www.worldpharmanews.net/Research_Development/Manhattan_Research_Releases_Report_on_the_Future_of_Physician_Customer_Service_Portals/</comments>
<pubDate>Wed, 19 Nov 2008 00:05:34 +0200</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/Manhattan_Research_Releases_Report_on_the_Future_of_Physician_Customer_Service_Portals/</guid>
<description><![CDATA[Over the past year, physician visitation to customer service portals decreased while interest in using them actually increased. To help biopharma companies bridge the gap between the current portal landscape and unmet physician demand, pharmaceutical and healthcare market research company Manhattan Research just released its latest physician module report, &quot;The Case for Customer Care: Service Portals and a Successfully Integrated CRM System&quot; as part of its ePharma Physician v8.0 market research and strategic advisory service. The report discusses future implications for physician customer service portals and reveals market data and best practices for biopharma companies looking to reach target audiences through this channel.<br/><br/>1 Vote(s) ]]></description>
</item>

</channel>
</rss>
